Faculty

Sherif S. Farag, PhD, MB,BS, FRACP, FRCPA

Kenneth Wiseman Professor of Medicine

Phone (317) 274-0843

Address

Joseph E. Walther Hall, Room R3 414
980 W. Walnut St.

Indianapolis , IN 46202

Titles & Appointments

Kenneth Wiseman Professor of Medicine
Adjunct Professor of Medical & Molecular Genetics
Program Leader - Bone Marrow Transplant

Education

1995 PhD University of Melbourne

1984 MB,BS University of Melbourne
Research

a) Development of novel approaches to hematopoietic stem cell transplantation, including safer approaches to alternate donor transplantation through depletion of alloreactive T cells, utilization of KIR mismatches between donor and recipient, harnessing Treg cells, and NKT cells. b) Development of novel agents and regimens for the treatment of multiple myeloma. This includes pre-clinical research of novel agents (drug development).
Publications

High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation.
Farag SS; Nelson R; Cairo MS; O'Leary HA; Zhang S; Huntley C; Delgado D; Schwartz J; Zaid MA; Abonour R; Robertson M; Broxmeyer H; Oncotarget 2017 Nov 27

Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.
Khawaja MR; Perkins SM; Schwartz JE; Robertson MJ; Kiel PJ; Sayar H; Cox EA; Vance GH; Farag SS; Cripe LD; Nelson RP Jr; American journal of hematology 2015 Feb

Killer Cell Immunoglobulin-Like Receptor Ligand Mismatching: To Match or Mismatch?
Farag SS; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015 Dec 10

Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation.
Vélez de Mendizábal N; Strother RM; Farag SS; Broxmeyer HE; Messina-Graham S; Chitnis SD; Bies RR; Clinical pharmacokinetics 2014 Mar

The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.
Altenburg JD; Farag SS; Expert opinion on investigational drugs 2014 Dec 13

Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine.
Davis T; Farag SS; International journal of nanomedicine 2013 Sep 16

Differential stem- and progenitor-cell trafficking by prostaglandin E2.
Hoggatt J; Mohammad KS; Singh P; Hoggatt AF; Chitteti BR; Speth JM; Hu P; Poteat BA; Stilger KN; Ferraro F; Silberstein L; Wong FK; Farag SS; Czader M; Milne GL; Breyer RM; Serezani CH; Scadden DT; Guise TA; Srour EF; Pelus LM; Nature 2013 Mar 13

In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies.
Farag SS; Srivastava S; Messina-Graham S; Schwartz J; Robertson MJ; Abonour R; Cornetta K; Wood L; Secrest A; Strother RM; Jones DR; Broxmeyer HE; Stem cells and development 2013 Feb 15

The potential role of Aurora kinase inhibitors in haematological malignancies.
Farag SS; British journal of haematology 2011 Oct 8

From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.
Zhang S; Farag SS; Expert opinion on investigational drugs 2011 May 26

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.
Farag SS; Maharry K; Zhang MJ; Pérez WS; George SL; Mrózek K; DiPersio J; Bunjes DW; Marcucci G; Baer MR; Cairo M; Copelan E; Cutler CS; Isola L; Lazarus HM; Litzow MR; Marks DI; Ringdén O; Rizzieri DA; Soiffer R; Larson RA; Tallman MS; Bloomfield CD; Weisdorf DJ; Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2011 Jun 21

Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
Farag SS; Wood LL; Schwartz JE; Srivastava S; Nelson RP Jr; Robertson MJ; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Jones DR; Leukemia 2011 Jan 21

Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.
Pelus LM; Farag SS; Stem cells and cloning : advances and applications 2011 Feb 27

A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP Jr; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010 Oct 20

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS; British journal of haematology 2010 Jun 15

Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
Nelson RP Jr; Yu M; Schwartz JE; Robertson MJ; Hromas R; Fausel CA; Vance GH; Dlouhy SR; Baute JA; Cox EA; Wood LL; Srivastava S; Robertson KA; Haut PR; Farag SS; Abonour R; Cornetta K; Cripe LD; Bone marrow transplantation 2010 Jan 11

Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP Jr; Cornetta K; Fausel CA; Farag SS; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010 Dec 4

The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.
Zhang S; Suvannasankha A; Crean CD; White VL; Chen CS; Farag SS; International journal of cancer. Journal international du cancer 2010 Dec 1

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.
Farag SS; Zhang S; Jansak BS; Wang X; Kraut E; Chan K; Dancey JE; Grever MR; Leukemia research 2009 Mar 3

Antimyeloma effects of a sesquiterpene lactone parthenolide.
Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H; Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 15

OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS; Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Aug 15
Clinical Interests

Stem cell transplant, multiple myeloma

Looking for patient care?

To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.

Find a doctor